Assay News and Research

RSS

New Journal presents techniques for finding new uses for approved drugs

Mary Ann Liebert, Inc., publishers is pleased to announce Drug Repurposing, Rescue, and Repositioning, a dynamic new peer-reviewed journal that will present techniques and tools for finding new uses for approved drugs—particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

12 Dec 2013

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.

From NanoString Technologies 11 Dec 2013

Scientists target protein-detection approach to systematically measure human repertoire of proteins

An international team of scientists led by Fred Hutchinson Cancer Research Center cancer proteomics expert Amanda Paulovich, M.D., has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets.

9 Dec 2013

Biocartis, VIB partner to develop novel MSI biomarkers for colorectal cancer

Today Biocartis and VIB announced their exclusive license agreement on a novel panel of microsatellite instability biomarkers for several cancers, in particular colorectal cancer.

From Biocartis 6 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Finnish healthcare company Biohit Oyj and American company Dynex Technologies, Inc. have signed an agreement for the distribution of the two-microplate DS2®, four-microplate DSX® and 12-microplate Agility® automated ELISA (enzyme-linked immunosorbent assay) processing systems, for use with the Biohit Oyj GastroPanel.

4 Dec 2013

VolitionRx's two-assay test can detect 85% of colorectal cancer, more than 50% of precancerous polyps

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition’s two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.

4 Dec 2013

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

NanoLogix, Inc. an innovator in the rapid detection, identification of live bacteria, and determination of their antibiotic resistance and sensitivity, announces that they are working with Nasaem-Aljazira, a Saudi Arabian company headquartered in Riyadh, to establish exclusive distribution and/or manufacturing of NanoLogix products in Saudi Arabia and the Arabian Gulf region, also known as the Gulf Cooperation Council (GCC) area.

4 Dec 2013

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

PrimeraDx, a molecular diagnostics company, announced today that the ICEPlex C. difficile Assay Kit and the ICEPlex System have received 510(k) clearance from the United States Food and Drug Administration.

3 Dec 2013

Xagenic announces closing of $20 million Series B financing

Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the close of a Series B financing totaling $20 million. The round was led by new investor Domain Associates, LLC, which was joined by existing investors including CTI Life Sciences Fund and the Ontario Emerging Technologies Fund.

2 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

New whitepaper examines main strategies employed to optimise target enrichment for NGS assays

Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing assays, assisting researchers to make informed decisions when designing studies.

From Oxford Gene Technology 30 Nov 2013

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

New methods for the laboratory-scale synthesis of coumarin-based drugs were developed in a recent study completed at the University of Eastern Finland. In his doctoral thesis, Lic. Phil. Juri Timonen also developed new analytical methods for the fast identification of natural and non-natural coumarins.

26 Nov 2013

Novel urinary antigen test boosts S. pneumoniae CAP detection

Research published in the European Respiratory Journal shows that addition of a serotype-specific urinary antigen detection test to existing diagnostic methods can increase the detection of Streptococcus pneumoniae community-acquired pneumonia by over a third.

25 Nov 2013

A High-speed, User-friendly Microplate Reader

An interview with Ville Hasslahti, discussing an advanced microplate reader that can cover a whole plate in 15 seconds or less.

From Hidex Oy 21 Nov 2013

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon DNA vaccine to prevent and treat this deadly virus.

20 Nov 2013

Serametrix launches new MDSC-based blood test for cancer patients

Serametrix Corporation has announced the launch of an important new blood test for cancer patients. The test measures a patient's level of circulating Myeloid Derived Suppressor Cells (MDSCs) that are known to decrease anti-tumor immunity and are associated with poor survival rates in cancer patients.

20 Nov 2013

New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

BBI Solutions, a world leader in immunoassay development and contract manufacturing, recently launched its unique range of Recombinant Fab Monoclonal Antibodies at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo, on July 28-August 31, 2013, in Houston, Texas.

19 Nov 2013

Volition’s NuQ-5mc assay detects 75% of patients with colorectal cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces the publication of preliminary data from an ongoing independent trial of one of its NuQ assays.

8 Nov 2013

Assay News and Research

New Journal presents techniques for finding new uses for approved drugs

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

Scientists target protein-detection approach to systematically measure human repertoire of proteins

Biocartis, VIB partner to develop novel MSI biomarkers for colorectal cancer

New method for counting tumor-fighting cells to predict ovarian cancer

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

VolitionRx's two-assay test can detect 85% of colorectal cancer, more than 50% of precancerous polyps

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

Xagenic announces closing of $20 million Series B financing

New biomarkers to improve diagnostics of prostate cancer

New whitepaper examines main strategies employed to optimise target enrichment for NGS assays

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

Novel urinary antigen test boosts S. pneumoniae CAP detection

A High-speed, User-friendly Microplate Reader

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Serametrix launches new MDSC-based blood test for cancer patients

New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

Volition’s NuQ-5mc assay detects 75% of patients with colorectal cancer

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News